News | July 18, 2011

NeuroSigma Licenses UCLA's Thin-Film Nitinol Stent Technology

July 18, 2011 — NSVascular Inc., a newly formed subsidiary of NeuroSigma Inc., has signed an exclusive license with the University of California Los Angeles (UCLA) covering its medical applications of thin-film nitinol (TFN) technology.

Nitinol is a superelastic nickel and titanium alloy with unique properties that allow deformation and subsequent full recovery of the original shape upon exposure to body heat.

NSVascular will focus on developing and commercializing TFN-covered stents for endovascular applications, with its first two applications being flow-diverting stents for intracranial aneurysms (IA) and stents for treating peripheral artery disease (PAD).

A multidisciplinary team, comprised of researchers from the UCLA Henry Samueli School of Engineering and Applied Science in collaboration with physicians from the David Geffen School of Medicine at UCLA, has been engaged in the development and the in vitro/in vivo testing of TFN-covered IA and PAD stents.


"For the past five years our engineering team has benefited from collaborating with a top-notch UCLA medical team, spearheaded by Dr. Dan Levi and Dr. Fernando Vinuela. I am looking forward to working closely with the experienced management team at NeuroSigma and NSVascular in commercializing this promising technology," said Greg Carman, Ph.D., UCLA professor of mechanical and aerospace engineering and a co-founder of NSVascular.

Intracranial Aneurysm (IA) Flow-Diverting Stent
Intracranial aneurysms result from weaknesses in cerebral blood vessels, which can rupture and lead to stroke and death.  It is estimated that up to one in fifteen people in the United States develop a brain aneurysm during their lifetime. The traditional method of surgical clipping to treat brain aneurysms is very invasive, requiring removal of a section of the skull. Since 1995, endovascular coils have gained popularity, now accounting for the majority of current procedures.

"Pre-clinical in vivo testing has shown a remarkable 100 percent aneurysm occlusion rate within minutes of treatment, an achievement unmatched by competing flow-diverting technologies," said Fernando Vinuela, M.D., director of UCLA's division of interventional neuroradiology and a co-founder and scientific advisor to NSVascular. "Furthermore, our TFN-covered flow-diverting stent keeps the flexibility of the delivery system allowing safer distal intracranial navigation and stenting of a larger number of aneurysms," he added.

The company believes that flow-diverting stents represent one of the fastest growing segments of the neurovascular market and may supplant intracranial coiling as the preferred treatment for certain aneurysms. Last month, in support of continuing preclinical trials at UCLA, NeuroSigma entered into a contract with the university to fund the development of prototype TFN-covered stents for use in upcoming human trials.

Peripheral Artery Disease (PAD) Stent

Ten million Americans suffer from PAD, a common circulatory problem in which narrowing of arteries can lead to a reduction in blood flow to the limbs and a possible precursor to amputation or death from heart attack and stroke.

The license with UCLA also includes the use of TFN-covered stents for the treatment of PAD.  Since 2009, under an NIH Challenge Grant, UCLA has been conducting in vivo pre-clinical trials to demonstrate that its TFN-covered stents may eventually be used for the treatment of PAD by remaining patent even in vessels as small as 3 millimeters.  A unique surface treatment of the university’s TFN film provides superhydrophylic properties, which greatly reduces the adherence of platelets.

For more information: www.neurosigma.com

Related Content

Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Abbott will end sales of the Absorb bioresorbable stent scaffold, pulling it off the market September 14, 2017.
Feature | Stents Bioresorbable| September 08, 2017 | Dave Fornell
September 8, 2017 — Abbott Vascular has announced it will end commercial sales of its Absorb bioresorbable vascular s
Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting| September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience
First European Patient Enrolled in Intact Vascular's TOBA II BTK Trial
News | Stents Peripheral| July 26, 2017
Intact Vascular Inc. recently announced that its Tack Optimized Balloon Angioplasty II Below the Knee (TOBA II BTK)...
First Patient Treated in U.S. Feasibility Study of LimFlow Critical Limb Ischemia Device
News | Peripheral Artery Disease (PAD)| July 17, 2017
LimFlow SA announced enrollment of the first patient in the U.S. feasibility study of the LimFlow Percutaneous Deep...
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Overlay Init